Extracellular vesicles with enhanced potency

Isolated extracellular vesicles or exosomes from mesenchymal stromal cells, enriched with specific metabolic pathway genes, address the challenge of mitochondrial dysfunction in PAH by normalizing glucose oxidation and improving mitochondrial function, thereby reducing PAH symptoms.

JP2024167178AInactive Publication Date: 2024-12-03UNITED THERAPEUTICS CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024113965
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-06-17
Filing Date
2024-07-17
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapeutic approaches for pulmonary hypertension, particularly pulmonary arterial hypertension (PAH), have been ineffective in targeting mitochondrial dysfunction, leading to progressive heart failure and high mortality rates due to challenges in modulating mitochondrial function.

Method used

Administration of isolated extracellular vesicles or exosomes derived from mesenchymal stromal cells, enriched with increased expression of genes in the glycolytic pathway, TCA cycle, and electron transport chain, to normalize mitochondrial glucose oxidation and improve cellular energy metabolism.

Benefits of technology

The extracellular vesicles or exosomes effectively reduce right ventricular systolic pressure in hypoxia-induced PAH models and enhance mitochondrial function, offering a potential therapeutic benefit for PAH and other conditions associated with mitochondrial dysfunction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167178000003
    Figure 2024167178000003
  • Figure 2024167178000004
    Figure 2024167178000004
  • Figure 2024167178000005
    Figure 2024167178000005
Patent Text Reader

Abstract

To provide improved therapeutic compositions and methods for treating pulmonary hypertension, such as by targeting a mitochondrial function.SOLUTION: Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is filed on June 17, 2016, the entire contents of which are incorporated herein by reference. This application claims priority to U.S. Provisional Patent Application No. 62 / 351,627, filed on 2006 / 02 / 13.

[0002] The present application describes a method for isolating extracellular vesicles, including exosomes, and a method for isolating exosomes from pulmonary arterial hypertension. Pulmonary hypertension, including pulmonary arterial hypertension (PAH), and conditions associated with mitochondrial dysfunction and the use of extracellular vesicles or exosomes in the treatment of diseases. [Background technology]

[0003] Pulmonary hypertension is a progressive, life-threatening disease characterized by increased pressure in the pulmonary blood vessels. Increased narrowing of the pulmonary circulation leads to increased stress on the right heart, which By definition, in cases of chronic pulmonary hypertension, Mean pulmonary artery pressure (mPAP) was >25mmHg at rest or >30mmHg during exercise (normal). For example, untreated pulmonary arterial hypertension is diagnosed with a mean of 2.8 Pulmonary arterial hypertension is a condition that causes death within 5 years. The pathophysiology is characterized by pulmonary vascular vasoconstriction and remodeling. In chronic PAH, There was new muscle formation in the pulmonary blood vessels, which were initially in a non-muscular state, and the pulmonary blood vessels, which were already in a muscular state, The vascular musculature of the affected blood vessels increases in circumference. The resulting increase in pulmonary artery pressure This results in progressive stress on the right heart, which in turn leads to reduced cardiac output and ultimately to right heart failure. leading to heart failure (M. Humbert et al., J. Am. Coll. Cardiol. 2004, 43, 13S-24S). P.A. H is a rare disorder, affecting 1-2 people per million. The average age of patients is 36 years. Only 10% of patients are over 60 years of age. (GE D'Alonzo et al., Ann. Intern. Med. 1991, 115, 343-349) .

[0004] Numerous mechanisms have been implicated in the pathogenesis of PAH. Suppression of global metabolism downstream of mitochondrial glucose oxidation has been described. Decreased doria function leads to the involvement of multiple cell types, cancer-like proliferation of pulmonary vascular cells, and apoptosis. Many apparently unrelated abnormalities in PAHs, such as the resistance of these cells to necrosis, have been reported. Evidence for a role of mitochondrial dysfunction in PAH Despite this, therapeutic targeting of mitochondrial function has proven difficult. . Summary of the Invention

[0005] Therefore, improved methods for treating pulmonary hypertension, such as by targeting mitochondrial function, are currently being investigated. There is a need to develop better therapeutic compositions and methods.

[0006] In one aspect, the disclosure provides a method of treating (including preventing) pulmonary hypertension, comprising administering to a subject a therapeutically effective amount of Administering isolated extracellular vesicles or exosomes derived from mesenchymal stromal cells to a subject in need thereof The isolated extracellular vesicles or exosomes are whole extracellular vesicles obtained from mesenchymal stromal cells. (a) Genes in the glycolytic pathway, compared to the average abundance of their expression products in vesicles or exosomes (b) a gene in the TCA cycle; and (c) a gene in the electron transport chain. The present invention relates to an extracellular vesicle or exosome having increased expression of one or more expression products. In some embodiments, the extracellular vesicles or exosomes are mesenchymal stem cells. Relative to the average levels of the same expression products in total extracellular vesicles or exosomes from stromal cells expression of at least 10%, 20%, 30%, 50%, or 100% greater expression product compared to Including the present.

[0007] In some embodiments, the isolated extracellular vesicles or exosomes comprise (a) a gene in the glycolytic pathway. (b) genes in the TCA cycle, and (c) genes in the electron transport chain. The expression of the protein(s) of the selected gene or genes is increased. In some embodiments, the isolated extracellular vesicles or exosomes comprise (a) genes in the glycolytic pathway; (b) a gene in the TCA cycle; and (c) a gene in the electron transport chain. Expression of the RNA(s) of one or more genes is increased.

[0008] In some embodiments, (a) the genes in the glycolytic pathway are PK, AGI, ALDO, ALD OA, ENO3, GPI, HK2, HK3, PFK, PGM, TPI, GAPDH, EN (b) the genes in the TCA cycle are selected from the group consisting of MDH2, from OGDH, PC, PDHA1, PDHB, SDHA, SDHC, and SUCLG2 and (c) the genes in the electron transport chain are selected from the group consisting of ETFA, ATPase, ND UFC2, NDUFB1, NDUFS5, NDUFA8, NDUFA9, NDUFS2, Selected from the group consisting of SDHA, SDHC, UQCRH1, Cox6c1, and Cox10 It is selected.

[0009] In some embodiments, the gene is PK. In some other embodiments, the gene is A TPase.

[0010] In some embodiments, the isolated extracellular vesicles or exosomes are In some embodiments, the isolated extracellular vesicles or exosomes are administered to a subject. Normalize glucose oxidation in lung tissue. In some embodiments, isolated extracellular vesicles or or exosomes have a PK activity of at least 0.15 nmol / min / mL.

[0011] In some embodiments, the isolated extracellular vesicles or exosomes are cultured under chronic hypoxic conditions for 3 weeks. The mice were exposed to 10% ethanol and showed a chronic hypoxia of at least 10% for 3 weeks compared to PBS-treated control mice. It can reduce right ventricular systolic pressure (RVSP) in mice exposed to oxygen.

[0012] In some embodiments, the isolated extracellular vesicles or exosomes are subjected to 24 hour hypoxia. At least 20%, 2 O2-induced hypoxia in smooth muscle cell (SMC) lysates exposed to 4 h hypoxia 2 Increase consumption It is possible.

[0013] In another aspect, the present disclosure provides a method for treating a disease or condition associated with mitochondrial dysfunction. The method comprises administering to a subject in need thereof isolated extracellular vesicles or and administering exosomes to the isolated extracellular vesicles or exosomes to a mesenchymal stroma. Compared to the average level of expression product in total extracellular vesicles or exosomes from cells (a) genes in the glycolysis pathway, (b) genes in the TCA cycle, and (c) genes in the electron transport chain. The expression of one or more expression products selected from the group consisting of genes of The method includes administering to the subject a sample containing the subject a vesicle or exosome.

[0014] In some embodiments, the isolated extracellular vesicles or exosomes comprise (a) a gene in the glycolytic pathway. (b) genes in the TCA cycle, and (c) genes in the electron transport chain. The expression of the protein(s) of the selected gene or genes is increased. In some embodiments, the isolated extracellular vesicles or exosomes comprise (a) genes in the glycolytic pathway; (b) a gene in the TCA cycle; and (c) a gene in the electron transport chain. Expression of the RNA(s) of one or more genes is increased.

[0015] In some embodiments, (a) the genes in the glycolytic pathway are PK, AGI, ALDO, ALD OA, ENO3, GPI, HK2, HK3, PFK, PGM, TPI, GAPDH, EN (b) the genes in the TCA cycle are selected from the group consisting of MDH2, from OGDH, PC, PDHA1, PDHB, SDHA, SDHC, and SUCLG2 and (c) the genes in the electron transport chain are selected from the group consisting of ETFA, ATPase, ND UFC2, NDUFB1, NDUFS5, NDUFA8, NDUFA9, NDUFS2, Selected from the group consisting of SDHA, SDHC, UQCRH1, Cox6c1, and Cox10 It is selected.

[0016] In some embodiments, the gene is PK. In some other embodiments, the gene is A In some embodiments, the isolated extracellular vesicles or exosomes are Normalize glucose oxidation in lung tissue. In some embodiments, isolated extracellular vesicles or or exosomes have a PK activity of at least 0.15 nmol / min / mL.

[0017] In some embodiments, the disease or condition associated with mitochondrial dysfunction is diagnosed in a subject. In some embodiments, the present invention is associated with a reduction in mitochondrial glucose oxidation in Diseases or conditions associated with mitochondrial dysfunction include Friedreich's ataxia, Leishmania, Bell's hereditary optic neuropathy, Kearns-Sayre syndrome, lactic acidosis and cerebrovascular accident-like episodes Mitochondrial encephalomyopathy with morphological features, Leigh syndrome, obesity, atherosclerosis, muscle Atrophic lateral sclerosis, Parkinson's disease, cancer, heart failure, myocardial infarction (MI), Alzheimer's disease, Huntington's disease, schizophrenia, bipolar disorder, fragile X syndrome, and chronic fatigue syndrome? The compound is selected from the group consisting of:

[0018] In another aspect, the present disclosure provides an extracellular vesicle or a medicament capable of treating or preventing pulmonary hypertension. A method for isolating extracellular vesicles or exosomes, comprising the steps of: (a) isolating extracellular vesicles or exosomes; (b) preparing a culture medium for mesenchymal stromal cells containing xosomes; Separating at least a portion of the extracellular vesicles or exosomes from the component; and (c) isolating an extracellular vesicle or exosome population from another extracellular vesicle or exosome population. The step of isolating, wherein the population is total extracellular vesicles or exosomal extracellular vesicles obtained from mesenchymal stromal cells. (a) genes in the glycolytic pathway, (b) TCA and (c) one or more genes selected from the group consisting of genes in the electron transport chain and wherein expression of a plurality of expression products is increased.

[0019] In another aspect, the present disclosure provides an extracellular vesicle or a medicament capable of treating or preventing pulmonary hypertension. A method for isolating extracellular vesicles or exosomes, comprising the steps of: (a) isolating extracellular vesicles or exosomes; (b) preparing a culture medium for mesenchymal stromal cells containing xosomes; (c) isolating at least a portion of the extracellular vesicles or exosomes from the component; (d) separating different populations of extracellular vesicles or exosomes based on molecular weight; Treating hypoxia-exposed mice with different populations of extracellular vesicles or exosomes , (e) Normoxia mice, hypoxia-exposed mice, and mice with extracellular vesicles or exosomal membrane proteins measuring right ventricular systolic pressure (RVSP) in the hypoxia-exposed mice treated with the therapy; and (f) a study to identify a robust population of extracellular vesicles or exosomes based on RVSP. The present invention provides a method comprising the steps of:

[0020] In some embodiments, hypoxia-exposed mice treated with extracellular vesicles or exosomes If the ratio of the RVSP of the mouse to the RVSP of the mouse exposed to hypoxia is 0.85 or less, The population of vesicles or exosomes is robust.

[0021] In some embodiments, the delta RVSP is less than 5 mmHg and the delta RVSP is RVSP negative oxygen positive in hypoxic exposed mice treated with extravesicular vesicles or exosomes In normal mice, the population of extracellular vesicles or exosomes is robust in RVSP .

[0022] In some embodiments, in step c, different types of extracellular vesicles or exosomes are The populations are separated by phospholipid detection.

[0023] In some embodiments, the enriched population of extracellular vesicles or exosomes is derived from mesenchymal stromal cells. Compared to the average amount of expression product in total extracellular vesicles or exosomes obtained from the vesicles (a ) genes in the glycolytic pathway, (b) genes in the TCA cycle, and (c) genes in the electron transport chain. The expression of one or more expression products selected from the group consisting of: In embodiments, the enriched population of extracellular vesicles or exosomes is a subset of (a) genetically engineered proteins in the glycolytic pathway. (b) a gene in the TCA cycle; and (c) a gene in the electron transport chain. There is increased expression of the protein(s) of one or more genes selected. In one embodiment, the enriched population of extracellular vesicles or exosomes is (a) a gene in the glycolytic pathway. (b) genes in the TCA cycle, and (c) genes in the electron transport chain. Expression of the RNA(s) of the selected gene or genes is increased.

[0024] In some embodiments, (a) the genes in the glycolytic pathway are PK, AGI, ALDO, ALD OA, ENO3, GPI, HK2, HK3, PFK, PGM, TPI, GAPDH, EN (b) the genes in the TCA cycle are selected from the group consisting of MDH2, from OGDH, PC, PDHA1, PDHB, SDHA, SDHC, and SUCLG2 and (c) the genes in the electron transport chain are selected from the group consisting of ETFA, ATPase, ND UFC2, NDUFB1, NDUFS5, NDUFA8, NDUFA9, NDUFS2, Selected from the group consisting of SDHA, SDHC, UQCRH1, Cox6c1, and Cox10 It is selected.

[0025] In some embodiments, the gene is PK. In some embodiments, the gene is ATP. It is ase.

[0026] In another aspect, the present disclosure provides an extracellular antibody capable of treating or preventing bronchopulmonary dysplasia. A method for isolating vesicles or exosomes, comprising the steps of: (a) isolating extracellular vesicles or exosomes; (b) providing a culture medium for mesenchymal stromal cells containing the exosomes; Separating at least a portion of the extracellular vesicles or exosomes from other components of the (c) separating different populations of extracellular vesicles or exosomes based on molecular weight; (d) Treatment of hypoxia-exposed mice with different populations of extracellular vesicles or exosomes. (e) Normoxia-exposed mice, hypoxia-exposed mice, and mice exposed to extracellular vesicles or A study was performed to measure right ventricular systolic pressure (RVSP) in mice exposed to hypoxia and treated with xosomes. and (f) identifying a strong population of extracellular vesicles or exosomes based on RVSP. The present invention provides a method comprising the steps of:

[0027] In some embodiments, step (b) of the method comprises performing size exclusion chromatography. This separates a portion of the extracellular vesicles or exosomes from other components of the culture medium.

[0028] In another aspect, the present disclosure provides an isolated cell obtained according to any of the methods described in this disclosure. Compositions comprising extracellular vesicles or exosomes are provided. In some embodiments, isolated cells The exosomal vesicles or exosomes have an average diameter of about 100 nm. Isolated extracellular vesicles or exosomes express FLOT and / or ANXA2. In some embodiments, the isolated extracellular vesicles or exosomes are total extracellular fractions of mesenchymal stromal cells. mir204 expression compared with the average amount of mir204 in vesicles or exosomes In some embodiments, the isolated extracellular vesicles or exosomes are CD105, GAPDH, DLST, and total extracellular vesicles or exosomes of stromal cells and / or ATP5A1 compared to the mean amounts of CD105, GAPDH, DLST, and and / or are secreted from MSCs that contain increased expression of ATP5A1. In an embodiment, the isolated extracellular vesicles or exosomes are whole extracellular vesicles of mesenchymal stromal cells. or SORCS1, FHIT and / or ANKRD30BL in exosomes SORCS1, FHIT and / or ANKRD30BL RNA compared to the average amount of In some embodiments, the isolated extracellular vesicles or exosomes are characterized by increased expression of MH In some embodiments, the isolated extracellular vesicles or exocytic vesicles are substantially free of CII contaminants. The fibrosomes are substantially free of fibronectin.

[0029] In another aspect, the disclosure provides a method of treating or preventing bronchopulmonary dysplasia, comprising: The isolated extracellular vesicles obtained according to any of the methods described herein are administered to a subject in need thereof. or exosomes. In some embodiments, isolated The extracellular vesicles or exosomes increase the immunomodulatory capacity of a subject. In some embodiments, The present invention relates to a method for the production of isolated extracellular vesicles or exosomes that can enhance the expression of IL-6 and / or TNF-α in a subject. In some embodiments, the isolated extracellular vesicles or exosomes reduce the expression of .alpha. In some embodiments, the isolated extracellular vesicles or exosomes are In some embodiments, the isolated cell is a subject. Extracellular vesicles or exosomes reduce cytochrome C levels in a subject. In embodiments, the isolated extracellular vesicles or exosomes increase mitochondrial metabolism in a subject. In some embodiments, the isolated extracellular vesicles or exosomes induce tubule formation in a subject. In some embodiments, the isolated extracellular vesicles or exosomes are administered to a subject. In some embodiments, the expression of the GLUD1 and / or PDH genes is upregulated. The isolated extracellular vesicles or exosomes down-regulate PDK4 gene expression in subjects. In some embodiments, the isolated extracellular vesicles or exosomes are used to detect SIRT4 genomic DNA in a subject. downregulates expression of

[0030] In some embodiments, the treatment or prevention of pulmonary hypertension and / or bronchopulmonary dysplasia The method further includes administering sildenafil to the subject.

[0031] The drawings provided are illustrative and not limiting of the disclosed subject matter. [Brief description of the drawings]

[0032] [Figure 1-1]Figure 1 shows the isolation of exosomes from MSC culture medium and their efficacy in preventing chronic hypoxia-induced PAH in mice. Figure 1A shows different exosome populations isolated based on size exclusion chromatography. Figure 1B shows an overlay of exosomes isolated by phospholipid concentration detection and A280 chromatograms. [Figure 1-2] Figure 1C shows the isolation of exosomes from MSC culture medium and their efficacy in preventing chronic hypoxia-induced PAH in mice. Figure 1C shows the effect of isolated exosomes in treating mice with hypoxia-induced PAH. A potent exosome population (EXM2 shown as green dots) prevented chronic hypoxia-induced PAH in mice, whereas the other exosome population (EXM1 shown as red dots) did not. [Diagram 2] Identification of potent exosome populations. Figure 2A shows pyruvate kinase activity of exosome populations plotted against fold change in RVSP between hypoxia-treated groups and hypoxia control. Figure 2B shows pyruvate kinase activity of exosome populations plotted against delta RVSP. Red dots represent potent exosome populations that induced significant improvement in RVSP. Blue dots represent exosome populations that were not potent in treating hypoxia-induced PAH mice. Figure 2C shows pyruvate kinase activity of potent exosome populations graphed in a box plot. [Diagram 3] Figure 3 illustrates the proteomic analysis of different exosome populations. Figure 3A shows that proteins with increased expression levels in the potent exosome population were involved in glycolysis, TCA cycle, and electron transport chain. Figure 3B shows the Western blot analysis of pyruvate kinase in both potent (EXM2) and non-potent (EXM1) exosome populations. [Figure 4]Figure 1 shows RNAseq analysis of different exosome populations. The results demonstrated that the potent exosome populations contained enriched genes involved in glycolysis, the TCA cycle, and the electron transport chain, suggesting the potential of the potent exosome populations for gene reprogramming to increase glucose oxidation (a). [Figure 5-1] Figure 5 shows O2 consumption assay in exosome-treated SMC cell lysates after 24 hours of exposure to either normoxia or 4% O2 hypoxia. Figure 5A shows O2 consumption calculated as the slope normalized to the PBS control. [Figure 5-2] Figure 5 shows O2 consumption assay in exosome-treated SMC cell lysates after 24 hours of exposure to either normoxia or 4% O2 hypoxia. Figure 5B shows O2 consumption calculated as area under the curve normalized to PBS control. The results in Figures 5A and 5B show that exosomes do not significantly alter cellular O2 consumption in normoxia-exposed SMCs. On the other hand, exosome treatment induced an increase in O2 consumption under hypoxic stress, indicating increased mitochondrial function. [Figure 6-1] 6A-6C illustrate the results of microarray analysis of SMC lysates following acute hypoxia exposure. Figure 6A shows increased ENO1 gene expression in glycolysis following hypoxia exposure, normalized by exosome treatment. [Figure 6-2] 6A-6C are diagrams illustrating the results of microarray analysis of SMC lysates after acute hypoxia exposure. FIG. 6B shows increased PDHB and ACLY gene expression in the TCA cycle after hypoxia exposure, normalized by exosome treatment. FIG. 6C shows increased NDUFAF3, ATP2B4, ATP5H, and ATP91 gene expression in the electron transport chain after hypoxia exposure, normalized by exosome treatment. [Figure 7-1] 7 shows metabolomic analysis of SMC lysates following acute hypoxia exposure: (A) shows the fold change in metabolite levels in glycolysis; (B) shows the fold change in metabolite levels in the TCA cycle. [Figure 7-2]Metabolomic analysis of SMC lysates after acute hypoxia exposure. Figure 7C shows the fold change in metabolite levels in the electron transport chain. Figure 7D shows a comparison of ATP generation in viable SMCs exposed to hypoxia with and without exosome treatment (# means p ≦ 0.05 compared to normoxia, $ means p ≦ 0.05 compared to hypoxia, * means p ≦ 0.1 compared to normoxia and p ≦ 0.1 compared to hypoxia). Results showed energy metabolism after hypoxia exposure with reduced glycolysis, metabolite construction in the TCA cycle, and flux through these pathways. Flux through these pathways was increased by exosome treatment, indicating that exosome treatment increases glucose oxidation and normalizes the SMC stress response to acute hypoxia. [Figure 8-1] 8 shows the analysis of SMC lysates after hypoxia exposure. Fig. 8A shows the activity of medium LDH in SMC lysates after 24 hours of hypoxia exposure. Fig. 8B shows the level of medium citrate in SMC lysates after 24 hours of hypoxia exposure. [Figure 8-2] Figure 8 shows the analysis of SMC lysates after hypoxia exposure. Figure 8C shows the activity of medium LDH in SMC lysates after chronic 2 weeks of hypoxia exposure. Figure 8D shows the level of medium citrate in SMC lysates after chronic 2 weeks of hypoxia exposure. [Figure 8-3] Analysis of SMC lysates after hypoxia exposure. Figure 8E shows protein expression of pyruvate dehydrogenase active subunit (PDHE1α), PDHE1α inhibitor pyruvate dehydrogenase kinase (PDK), and ATPase in SMC lysates after chronic 2-week hypoxia exposure (# means p≦0.05 compared to normoxia, $ means p≦0.05 compared to hypoxia, * means p≦0.1 compared to normoxia and p≦0.1 compared to hypoxia). The results show that exosome treatment normalizes mitochondrial function after acute and chronic hypoxia exposure. [Figure 9]Figure 1. Presented model for exosome therapy. In particular, pulmonary hypertension suppresses mitochondrial glucose oxidation, resulting in impaired systemic mitochondrial function. Exosome therapy normalizes glucose oxidation and improves mitochondrial capacity both through glycolysis (1) and through acute phase protein incorporation and / or chronic genetic upregulation of enzymes in the TCA cycle and electron transport chain within mitochondria (2). [Figure 10] Comparison of chromatograms of exosomes generated without (blue) and with (orange) diafiltration step. The blue chromatogram has a much higher A280 reading than the orange one, suggesting a higher amount of protein in the sample compared to the diafiltered sample. The diafiltration step is similar to a buffer exchange, which involves adding PBS buffer to the vessel to maintain volume while continuing to pump the TFF cassette filter after the desired concentration of exosomes is reached. Gradually, the PBS replaces the conditioned medium. To complete the exchange as much as possible, 7 total volumes of diafiltration were performed on the retentate. This step helps to remove some of the impurities in the retentate without affecting the exosomes. The presence of exosomes was confirmed by FLOT-1 Western blot. This figure shows that the diafiltration step helps to remove impurities as indicated by the low amount of total protein and phospholipids in the exosome retentate. [Figure 11] Figure 11 shows an exosome production analysis: Figure 11A shows a FLOT-1 Western blot analysis of 12 samples; Figure 11B shows the size distribution of exosomes, with a mean diameter of about 100 nm. [Figure 12] FIG. 13 shows exemplary supplemental analyses and evaluations of exosome production, including chromatograms, NTA, FLOT-1 Western blot, and ANXA2 Western blot. [Figure 13]Analysis of potent exosomes. Figure 13A shows chromatograms of COM1 (large, non-potent exosome population) and COM2 (small, potent exosome population). Figure 13B shows plots of total protein against RVSP (in an animal model of hypoxia-induced pulmonary hypertension) from each preparation compared to hypoxic control. The results show that the resulting preparation is potent when there is more protein in the large, non-potent fraction. Figure 13C shows plots of total protein against days of feeding before starvation. The results show that the positive delta protein (designated potent preparation) was fed continuously in both preparations for 1 day before starvation. [Figure 14] Plotting of mir204, a small non-coding RNA molecule containing approximately 22 nucleotide functional groups in RNA silencing and post-transcriptional control of gene expression. COM1 has high cycle threshold (CT) values ​​and low potency, corresponding to small miRNAs. In contrast, COM2 has increased mir204 expression. [Figure 15] Figure 15 shows that exosome efficacy is positively correlated with CD105 protein expression (Figure 15A), GAPDH gene expression (Figure 15B), DLST gene expression (Figure 15C), and ATP5A1 gene expression (Figure 15D) in parental MSC cells. The results indicate that the metabolic health of cells is directly related to exosome efficacy. [Figure 16] FIG 16 shows impaired lung development in patients with bronchopulmonary dysplasia (BPD). FIG 16A shows x-rays of different stages of BPD. FIG 16B shows alveolar damage in a mouse model. [Figure 17] Figure 1. In vitro model of hyperoxia and unexisome-mediated suppression of inflammation: Alveolar cells were seeded for 24 h, transferred to 0.1% FBS medium, primed with a potent exosome population (unexisome) for 3 h in a normoxic incubator, and plated in a hyperoxic incubation chamber for 48 h. [Figure 18]Figure 1: A potent exosome population (unexisomes) increases immunomodulatory capacity in cells exposed to hyperoxic stress based on the decreased expression of IL-6 (hyperoxic conditions cause the release of IL-6). "#" indicates significance of exosome treatment compared to normoxic controls. "*" indicates significance of exosome treatment compared to hyperoxic controls. [Figure 19] FIG. 1 shows that a potent exosome population (unexisomes) increases immunomodulatory capacity in cells exposed to hyperoxic stress based on the downregulation of TNFα (hyperoxic conditions cause the release of TNFα). "*" indicates significance of exosome treatment compared to hyperoxic control. [Figure 20] FIG. 1 shows that a potent exosome population (unexisomes) has an anti-apoptotic effect under hyperoxia as shown by increased absorbance corresponding to increased cell numbers. "*" indicates significance of exosome treatment compared to hyperoxia control. [Figure 21] Figure 1: A potent exosome population (unexisomes) reduces cytochrome C release from cells exposed to hyperoxic stress, which corresponds to reduced cell apoptosis. * indicates significance of exosome treatment compared to hyperoxic control. [Figure 22] Figure 22A shows fluorescent images of normoxic cells, cells exposed to hyperoxic stress, and cells treated with potent exosomes. Figure 22B shows that exosome (COM2) treatment restores tube formation in hyperoxic conditions. [Diagram 23]Schematic of smooth muscle cell (SMC) chronic hypoxia model. SMCs change to a proliferative, non-apoptotic phenotype in PAH and hypoxia, leading to vascular and arterial hypertrophy in the lungs, high pressure, and ultimately damage to the heart / negative symptoms in PAH. SMCs were cultured in normoxia, 4% oxygen, and 4% oxygen + exosomes. During the culture period, cells were treated with potent exosomes twice a week for 2 weeks. Generated SMCs were analyzed by microarray gene expression (IPA) and / or global metabolomics. [Figure 24] FIG. 1 shows that exosomes upregulate amino acid metabolism in chronic hypoxia by global metabolite analysis of intermediate metabolites within the pathway. [Diagram 25] FIG. 1 shows that exosomes upregulate pyruvate and glutamate metabolism during chronic hypoxia. [Figure 26] FIG. 1 shows that exosomes upregulate GLUD1 gene expression under chronic hypoxic conditions. [Figure 27] FIG. 1 shows that exosomes downregulate PDK4 under chronic hypoxia. [Figure 28] Figure 1: Exosomes down-regulate SIRT4 in chronic hypoxia. SIRT4 gene inhibits two metabolic enzymes, GLUD1 and PDH, in an in vitro PAH model. SIRT4 gene is down-regulated by exosome treatment in an in vitro PAH model, while GLUD1 and PDH are up-regulated by exosome treatment. SIRT4 is considered to be a target for exosome treatment. [Figure 29] FIG. 1 shows that exosomes restore TCA cycle function by upregulating genes that are downregulated in hypoxia (6 out of 9 enzymes in the TCA cycle are downregulated). [Diagram 30] FIG. 1 shows the relationship between SIRT4 and exosome therapy. [Diagram 31]Figure 1. Proposed mechanism of potent exosomes in repairing the TCA cycle. Specifically, hypoxia inhibits TCA cycle function by (1) upregulating SIRT4 and PDK4, both of which inhibit PDH and thus pyruvate entry into the TCA cycle, and (2) upregulating SIRT4, which inhibits GLUD1 and thus glutamine entry into the TCA cycle. Potent exosomes (unexosomes) reduce both SIRT4 and PDK4, thereby increasing the flux of glutamine and pyruvate into the TCA cycle. [Diagram 32] FIG. 1 shows isolation of a robust exosome population (COM2) using size exclusion chromatography compared to ultracentrifugation or gradient separation, which isolate not only non-ideal sized exosomes but also protein and non-strong microvesicle contaminants. [Diagram 33] Figure 1 shows TEM imaging of exosomes. The results show that isolated potent exosomes have a more uniform size and clearer images compared to ultracentrifuged samples. [Diagram 34] Figure 1 shows that isolated potent exosomes are free of MHCII contaminants. In contrast, commercially available exosomes from ZenBio contain MHCII contaminants. [Diagram 35] Based on Ponceau staining, isolated potent exosomes are free of fibronectin and other protein contaminants. Figure 35A shows that isolated exosomes are free of the contaminating protein fibronectin, while the commercially available ZenBio ultracentrifugation preparation has fibronectin contaminants. Figure 35B shows that exosomes isolated by ultracentrifugation contained fibronectin contaminants similar to concentrated cell culture media. Exosomes isolated by size exclusion chromatography are free of fibronectin contaminants and other protein contaminants that can be stained by Ponceau. [Diagram 36]Figure 2 shows RNAseq clustering analysis of the potent population and microvesicle contaminants. The results show that potent exosomes (COM2) cluster differentially from the microvesicle contaminants, and are enriched in SORCS1, FHIT, and ANKRD30BL. [Figure 37] Figure 1 shows GAPDH expression in potent exosomes (COM2) versus non-potent exosomes (COM1). The results show that potent exosomes have low C values ​​corresponding to high expression levels of GAPDH. [Figure 38] FIG. 1 shows the procedure for in vivo testing of a BPD mouse model treated with potent exosomes (unexosomes). [Figure 39] Characterization of exosomes used in in vivo studies. Figure 39A shows that the concentration of exosomes is 1.2 x 108 particles / mL. Figure 39B shows that FLOT1 is present in exosomes based on Western blot analysis. Figure 39C shows representative TEM imaging of exosomes. [Diagram 40] Figure 40 shows that exosomes reduced BPD-associated alveolar compaction. Figure 40A shows that potent exosome treatment rescues hyperoxia (HYRX)-mediated increased alveolar compaction compared to normoxia (NRMX). Figure 40B shows quantification of mean alveolar diameter, which represents a surrogate for mean air space diameter. [Diagram 41] FIG. 1 shows the procedure for in vivo study of BPD-induced PAH mouse model of post-BPD PAH treated with potent exosomes (unexosomes). [Diagram 42] Figure 42 shows that exosomes rescued chronic alveolar simplification. Figure 42A shows images of cells under normoxic and hypoxic conditions, and cells treated with Wharton's jelly-derived exosomes and bone marrow-derived exosomes. Figure 42B shows that exosomes rescued alveolar simplification in a BPD-associated PAH mouse model. Figure 42C shows that exosomes reduced low-grade pulmonary fibrosis, as indicated by collagen deposition in the septal field, in a BPD-associated PAH mouse model. [Diagram 43] Figure 1. Exosomes rescue PAH pulmonary vascular remodeling, as demonstrated by α-smooth muscle actin staining (A and B) and pressure changes associated with PAH (C). PV-loops demonstrate a significant shift in hyperoxic (HYRX) mice, characteristic of emphysema-like lung disease and air trapping when compared to normoxic (NRMX) controls. Exosomes showed significant rescue of this shift, indicating improved lung function. [Diagram 44] Figure 44A shows the procedure for in vivo testing of hypoxia-induced PAH mouse model treatment, and Figure 44B shows that MSC exosomes prevent PAH in mice. [Diagram 45] Figure 45A shows the procedure for in vivo study of Sugen (VEGF receptor agonist) and hypoxia-induced PAH mouse models treated with a combination of exosomes and sildenafil. Figure 45B shows that combination therapy with exosomes and sildenafil reversed PAH in the mouse model. [Figure 46] FIG. 1 shows the procedure for identifying exosome-mediated mechanisms of action in PAH. [Figure 47] FIG. 1 shows that exosomes upregulate amino acid metabolism in the Sugen / hypoxia model of PAH. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] Some MSC extracellular vesicles or exosomes (e.g., bone marrow MSC extracellular vesicles or Exosomes) can enhance glucose oxidation and normalize mitochondrial function Thus, these extracellular vesicles or exosomes may mediate the secretion of PAHs and mitochondria. The present invention can provide a therapeutic benefit in diseases or conditions associated with functional impairment. reported that potent extracellular vesicles or vesicles efficiently prevented hypoxia-induced PAH in mice. We isolated a population of extracellular vesicles or exosomes. By genomics and RNAseq analysis, they were identified as involved in the glycolysis pathway, the TCA cycle and electron transport. It is shown that the gene contains a high expression level in the system. Exosomes express high levels of pyruvate kinase (PKM2) and ATPase, The present inventors have demonstrated that pulmonary artery smooth muscle is responsive to acute hypoxia. Exposure of SMCs to α-aminobutyric acid reduced the expression of numerous genes involved in glycolysis, the TCA cycle, and the electron transport chain. They also found that hypoxia leads to upregulation of extracellular vesicles or exosomula. Treatment of SMCs with a robust cohort of mice normalized these gene signatures. Furthermore, based on global metabolomic analysis, the strong role of extracellular vesicles or exosomes Population enhances glycolysis and ATP production in hypoxic exposed SMCs. Although it is not desirable, a strong population of extracellular vesicles or exosomes is involved in the glycolysis pathway, the TCA cycle, and / or gene reprogramming and protein assembly within key pathways such as the electron transport chain. Both may improve mitochondrial function in target cells ( See Figure 9).

[0034] In some embodiments, the extracellular vesicles or exosomes of the present invention express PDH and GLUD1. This increases the expression of β-lactamase (C-lactamase) and therefore increases flux into the TCA cycle.

[0035] Without wishing to be bound by theory, a strong population of extracellular vesicles or exosomes is Inhibition of SIRT4, a well-known inhibitor of both PDH and GLUD1, reduced the levels of PDH and GLUD1. Thus, in some embodiments, extracellular vesicles or Or exosomes increase the function of the TCA cycle.

[0036] Treatment of pulmonary hypertension including PAH, and diseases and conditions associated with mitochondrial dysfunction It is contemplated that the present invention may have application in the treatment of various conditions.

[0037] A.Definition Unless otherwise specified, "a" or "an" means "one or more."

[0038] Unless specifically defined otherwise, all technical and scientific terms used herein are understood to be within the skill of the art. shall be considered to have the same meaning as commonly understood by those skilled in the art.

[0039] Unless otherwise indicated, the recombinant proteins, cell culture, and immunological techniques utilized in this disclosure are standard procedures well known to those skilled in the art. Such techniques are described in J. Perbal, A Pract ical Guide to Molecular Cloning, John Wiley and Sons(1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press(198 9), T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Vol. umes 1 and 2, IRL Press(1991), DM Glover and BD Hames (editors), DNA Cloning g: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and FM Ausube l et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associat es and Wiley-Interscience (1988, including all current editions), Ed Harlow a nd David Lane (editor) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory ratory,(1988),and J. E. Coligan et al. (eds.) Current Protocols in Immunology, Mentioned throughout the literature in sources such as John Wiley & Sons (including all current editions) and described herein, which are incorporated by reference.

[0040] As used herein, the term "subject" (also referred to herein as "patient") refers to any warm-blooded animal, Preferably, the subject is a mammal, including a human. In a preferred embodiment, the subject is a primate. In more preferred embodiments, the subject is a human.

[0041] As used herein, the terms "treating," "treat," or "treatment" refer to a vascular disorder. The present invention includes reducing, alleviating, or eliminating at least one symptom of the disease.

[0042] As used herein, the terms "preventing," "prevent" or "prevention" refer to a vascular disorder. The term includes the cessation or interruption of the appearance or presence of at least one symptom of.

[0043] As used herein, the term "expression" refers to the RNA expression and / or expression of one or more genes. or protein expression levels. In other words, the term "expression" refers to RNA expression or The term can refer to either protein expression or

[0044] As used herein, the term "hypoxic conditions" refers to atmospheric O 2 Concentration, less than 20% oxygen (O 2 In some embodiments, hypoxia refers to a state having an oxygen concentration between 0% and 10%, Between 0% and 5% O 2 , between 5% and 10%, or between 5% and 15% 2 With concentration In one embodiment, hypoxia refers to a state in which the oxygen levels in the blood are reduced by approximately 10% O 2 Refers to the concentration of oxygen.

[0045] As used herein, the term "normoxia" refers to a condition that is similar to the normal atmospheric concentration of oxygen, approximately 20% to 21%. %O 2 It refers to the state of having.

[0046] As used herein, the term "isolate" or "isolated" refers to a compound that is isolated from a cell culture or medium. When used in the context of isolated extracellular vesicles or exosomes, Exosomes are extracellular vesicles or exosomes that exist away from their natural environment.

[0047] As used herein, the term "extracellular vesicles" includes exosomes.

[0048] As used herein, the term "extracellular vesicle or exosome population" refers to a population of exosomes that has unique properties. The term "extracellular vesicles or exosomes" refers to a population of extracellular vesicles or exosomes that We use the terms "population of extracellular vesicles" and "exosomes" interchangeably to describe cellular components with unique properties. It can refer to a population of extracellular vesicles or exosomes.

[0049] As used herein, the term "mesenchymal stromal cells" includes mesenchymal stem cells. , bone marrow, blood, dental pulp cells, adipose tissue, skin, spleen, pancreas, brain, kidney, liver, heart, retina, In the brain, hair follicles, intestine, lungs, lymph nodes, thymus, bones, ligaments, tendons, skeletal muscles, dermis, and periosteum These are cells that can be seen.

[0050] Mesenchymal stem cells can differentiate into different germ lineages, such as mesoderm, endoderm, and ectoderm. Mesenchymal stem cells can therefore be used to produce fat, bone, cartilage, elastic, muscle, and fibrous tissue. They can differentiate into many cell types, including but not limited to tissues. The specific lineage commitments and differentiation pathways entered by cells are subject to various influences, including mechanical effects. and / or endogenous bioactive factors such as growth factors, cytokines, and / or host It depends on the local microenvironmental conditions established by the host tissue. They are hematopoietic progenitor cells that divide to produce daughter cells that are either stem cells or progenitor cells. They eventually irreversibly differentiate into cells of a single phenotype.

[0051] Some embodiments of the present invention relate to extracellular vesicles or exosomal cells of mesenchymal stromal cells, broadly defined. These are synonymous with extracellular vesicles or exosomes of mesenchymal stromal cells. or extracellular vesicles or exosomes of MSCs, or This refers to the

[0052] B. Vascular disorders Vascular disorders include pulmonary hypertension, such as pulmonary arterial hypertension (PAH), peripheral vascular disease (PV D), critical limb ischemia (CLI), coronary artery disease, and diabetic vascular disease. is not limited to.

[0053] Pulmonary hypertension, such as pulmonary arterial hypertension (PAH), is a condition in which pressure in the pulmonary circulation increases and eventually PAH is a condition that ultimately leads to heart failure and death. Many causes and conditions are associated with PAH. Many of them share some common underlying pathophysiological features. One distinction between these processes is that they regulate vascular status and repair and inhibit clot formation. This is a dysfunction of the endothelium, the inner cell layer of the entire blood vessel wall, which is normally responsible for the production and metabolism of many of the substances that cause In PAH, endothelial dysfunction leads to the overproduction of harmful substances and impaired production of protective substances. This may be a key event in the development of PAH or part of the downstream cascade. It remains unknown whether this is the case, but if so, it characterizes the disease. The present invention relates to isolated extracellular vesicles or extracellular vesicles. Methods of treating pulmonary hypertension, including PAH, using xoxosomes are provided.

[0054] The term peripheral vascular disease (PVD) refers to damage, dysfunction or blockage in the peripheral arteries and veins. Peripheral arterial disease is the most common type of PVD. It is a very common condition in the United States, affecting mostly people over the age of 50. Peripheral vascular disease occurs among people over the age of 50 and in people with diabetes. Approximately 10 million people in the United States have peripheral vascular disease, which is the leading cause of disability in the United States. This translates to about 5% of people over the age of 50. The number of people with the condition increases with the age of the population. Men are slightly more likely than women to have peripheral vascular disease.

[0055] Critical limb ischemia (CLI), caused by the progression of peripheral arterial occlusion, reduces blood flow and oxygen at rest. Characterized by decreased delivery of steroids, muscle pain at rest and non-healing skin ulcers or gangrene (Rissanen et al., Eur. J. Clin. Invest. 31:651-666 (2001); Dormandy and Rutherford, J. Vasc. Surg. 31:S1-S296 (2000). Critical limb ischemia occurs in approximately 100,000 individuals per year. It is estimated that 500 to 1,000 people per 10,000 develop the disease (Second European Congress ensus Document on Chronic Critical Leg Ischemia”, Circulation 84 (4Suppl.) IV 1 -26 (1991)). In patients with critical limb ischemia, the associated morbidity, mortality, and functional outcomes are Despite this, amputation is often recommended as a solution to disabling symptoms (M. R. Tyrrell et al., Br. J. Surg. 80: 177-180 (1993); M. Eneroth et al., Int. Ort. hop. 16: 383-387 (1992)). There is no optimal treatment for severe lower limb ischemia (Circulation 8 4 (4 Suppl.): IV 1-26 (1991)).

[0056] Coronary artery disease (atherosclerosis) occurs when one or more coronary arteries become clogged with plaque. It is a progressive disease in humans in which the pulmonary circulation gradually becomes obstructive due to the The coronary artery was treated with balloon angioplasty or insertion of a stent to partially block it Ultimately, these patients will undergo coronary surgery at great expense and risk. He will need to undergo vascular bypass surgery.

[0057] Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants. It is characterized by persistent pulmonary inflammation, pulmonary Abnormal vascular proliferation with decreased alveolar number and enlargement of the alveolar septa, "pruning" of terminal blood vessels, and Characterized by limited metabolic and antioxidant capacity. 0 new cases of BPD. Importantly, the diagnosis of BPD is associated with a higher incidence of PAH, emphysema, and asthma. Increased rates of cardiovascular disease and postnatal mortality, neurodevelopmental disorders and cerebral palsy This often leads to other further conditions, including emphysema in adolescents. There is no standard treatment for BPD. Some patients with BPD are treated with moderate ventilation and corticosteroids. However, these treatments have no effect on neurological outcomes or death. The main risk for uterine malformation occurs in infants between 24 and 28 weeks of age, which corresponds to the early stages of pouch development. Infants at high risk weigh 1.3 to 2.2 pounds.

[0058] In one embodiment, the exosomes of the present invention can be used to treat BPD. In some embodiments, the exosomes increase the immunomodulatory capacity of the lung. In some embodiments, exosomes promote angiogenesis in the lung. Increases mitochondrial metabolism.

[0059] C. Mitochondrial dysfunction Mitochondria are intracellular organelles that perform several metabolic transformation and regulatory functions. Mitochondria generate most of the ATP used by eukaryotic cells. Tochondria are the main source of free radicals and reactive oxygen species that cause oxidative stress. As a result, mitochondrial defects lead to high energy demands. It is especially harmful to nerve and muscle tissue. Energy deficiencies therefore lead to movement disorders. , and has been implicated in forms of cardiomyopathy, myopathy, blindness, and deafness (DiMauro et al. (2001) Am. J. Med. Genet. 106, 18-26; Leonard et al.(2000) Lancet. 355, 299-304). Dysfunction may be associated with increased lactate production, decreased respiration and ATP production. Endorheic dysfunction may occur as a result of oxidative stress.

[0060] The present invention provides a method for treating a disease or condition associated with mitochondrial dysfunction. Mitochondrial dysfunction is characterized by reduced mitochondrial glucose oxidation in subjects. May be relevant.

[0061] In some embodiments, the disease or condition associated with mitochondrial dysfunction is Dreich's ataxia, Leber's hereditary optic neuropathy, Kearns-Sayre syndrome, lactic acidosis Mitochondrial encephalomyopathy with cerebrovascular accident-like symptoms, Leigh syndrome, obesity, Alzheimer's disease, Atherosclerosis, amyotrophic lateral sclerosis, Parkinson's disease, cancer, heart failure, myocardial infarction (MI), Alzheimer's disease, Huntington's disease, schizophrenia, bipolar disorder, fragile X syndrome and chronic fatigue syndrome.

[0062] D. Mitochondrial Energy Production Eukaryotic cells require energy to carry out cellular processes. The energy required for the synthesis is stored primarily in the phosphate bonds of adenosine 5'-triphosphate ("ATP"). (1) glycolysis, (2) the TCA cycle (also called the Krebs cycle or citric acid cycle), and (3) specific pathways that generate energy in eukaryotes, including oxidative phosphorylation. For ATP to be synthesized, carbohydrates must first be added to simple sugars (e.g., glucose). The lipids are hydrolyzed into fatty acids and glycerol. Similarly, proteins are hydrolyzed into amino acids. The energy in the chemical bonds of these hydrolyzed molecules is then released. It is then utilized by the cell to form ATP molecules through a number of catabolic pathways.

[0063] The main source of energy for living organisms is glucose. During glucose breakdown, the glucose molecule The energy in the chemical bonds is released and can be used by cells to form ATP molecules. This happens through a process that involves several steps. The first step is called glycolysis, in which The glucose molecule is broken down into two smaller molecules called pyruvate.

[0064] In glycolysis, glucose and glycerol are metabolized to pyruvate via the glycolytic pathway. During this process, two ATP molecules are produced. Two NADH molecules are also produced, which are It can be further oxidized via the electron transport chain, resulting in the generation of additional ATP molecules.

[0065] Glycolysis is the process by which many enzymes break down glucose (and other monosaccharides) into two molecules of pyruvate. In exchange, this pathway results in the production of a total of two molecules of ATP. The pyruvate molecules resulting from the pathway enter the mitochondria from the cytosol. These The molecule is converted to acetyl-coenzyme A (acetyl-CoA) for entry into the TCA cycle The TCA cycle is a process in which acetyl coenzyme A and oxaloacetate combine to produce citrate. The citric acid formed is then converted through a series of enzyme-catalyzed steps to It is broken down to produce an additional ATP molecule.

[0066] The energy released from the TCA cycle in the mitochondrial matrix is ​​converted into NADH( Complex I) and FADH 2 (complex II) enters the mitochondrial electron transport system. These are the first two of five protein complexes involved in ATP production, both of which are myosin-dependent. It is localized in the inner mitochondrial membrane. (Oxidized by NADH-specific dehydrogenase) N Electrons derived from ADH and FAD3 / 4 (by oxidation with succinate dehydrogenase) are released. They translocate to the endothelium and out of the mitochondrial matrix into the inner membrane space (i.e., the mitochondrial Induce active transport of protons (across the inner membrane) in discrete steps The electron carriers in the respiratory chain include flavins, protein-bound iron, -Sulfur centers, quinones, cytochromes, and copper. Two molecules that transfer electrons between complexes Present: Coenzyme Q (complex I → III, and complex II → III) and cytochrome P450 Chromium c (complex III → IV). The final electron acceptor in the respiratory chain is complex IV (3 / 4, will be converted to 3 / 40.

[0067] Some embodiments of the present invention provide inhibitors of glycolysis, the TCA cycle, and / or the electron transport chain. Extracellular vesicles or exosomes with increased expression of at least one gene or protein In some embodiments, the gene is selected from the group of genes represented by Table 1 below. Be selected.

[0068] [Table 1]

[0069] In some embodiments, the genes in the glycolytic pathway are PK, AGI, ALDO, ALDOA, ENO3, GPI, HK2, HK3, PFK, PGM, TPI, GAPDH, ENO, and PGAM.

[0070] In some embodiments, the genes in the TCA cycle are MDH2, OGDH, PC, PDHA 1, PDHB, SDHA, SDHC, and SUCLG2.

[0071] In some embodiments, the genes in the electron transport chain are ETFA, ATPase, NDUFC 2, NDUFB1, NDUFS5, NDUFA8, NDUFA9, NDUFS2, SDH A, SDHC, UQCRH1, Cox6c1, and Cox10. do.

[0072] In some embodiments, the extracellular vesicles or exosomes have increased expression of PK.

[0073] In some embodiments, the extracellular vesicles or exosomes have increased expression of ATPase. is.

[0074] In some embodiments, the extracellular vesicles or exosomes are characterized by the expression of PK and ATPase. It is increasing.

[0075] E. Extracellular vesicles isolated from mesenchymal stromal cells The extracellular vesicles or exosomes of the present invention are, for example, membrane-separated vesicles from mesenchymal stromal cells. They can be (e.g., lipid bilayer) vesicles. They can be, for example, in the range of about 30 nm to 100 nm. By electron microscopy, extracellular vesicles or exosomes can be seen to have a cup-like shape. They may sediment at, for example, about 100,000 × g. , and has a bouillon density in sucrose of about 1.10 to about 1.21 g / ml.

[0076] Mesenchymal stromal cells can be derived from bone marrow, blood, periosteum, dermis, umbilical cord blood and / or matrix (e.g. Several sources, including but not limited to, cerebrospinal fluid (e.g., Wharton's jelly), and placenta, The method for obtaining mesenchymal stromal cells is described in more detail in the Examples. For other collection methods that can be used in the present invention, see the following references: See also U.S. Pat. No. 5,486,359, incorporated herein by reference.

[0077] The mesenchymal stromal cells contemplated for use in the methods of the present invention and thus the extracellular vesicles or extracellular Xosomes can be obtained from the same subject to be treated (and therefore autologous to the subject). ), or they can be obtained from different subjects, preferably from subjects of the same species (so (These individuals can be considered allogeneic to the subject.)

[0078] As used herein, aspects and embodiments of the invention relate to cells, unless otherwise indicated. and cell populations. Thus, unless otherwise indicated, cells are listed. It should be understood that when used in combination, cell populations are also contemplated.

[0079] Some aspects of the present invention refer to isolated extracellular vesicles or exosomes. As used herein, isolated extracellular vesicles or exosomes are physically separated from their native environment. Isolated extracellular vesicles or exosomes are isolated extracellular vesicles or exosomes. endothelial stromal cells, in whole or in part, from the tissue or cellular environment in which they originated In some embodiments of the present invention, isolated extracellular vesicles or The composition of exosomes may not contain cells such as mesenchymal stromal cells, or the composition may be The composition may be free or substantially free of conditioned medium. The isolated extracellular vesicles or exosomes were analyzed by measuring the amount of extracellular vesicles or exosomes present in untreated conditioned medium. They can be provided in higher concentrations than exosomes. Extracellular vesicles or exosomes are From the culture medium, mesenchymal stromal cells can be isolated from the culture.

[0080] In general, magnetic particles, filtration, dialysis, ultracentrifugation, ExoQuick™ (System ms Biosciences, CA, USA), and / or chromatography. Any suitable method for the purification and / or enrichment of extracellular vesicles or exosomes, such as those described herein, may be used. Any method can be used. In some embodiments, centrifugation and / or ultracentrifugation are used. Isolate extracellular vesicles or exosomes by centrifugation. The microbial strains can also be purified by ultracentrifugation of clarified conditioned medium. Purification can also be achieved by ultracentrifugation into a cushion. See, for example, Thery et al. Current Protocols in Cell B, incorporated herein by reference. iol. (2006) 3.22. In some embodiments, a one-step size exclusion Isolate extracellular vesicles or exosomes by chromatography. The method is described, for example, in Boing et al. Journal of Extrac Mesenchymal stromal cells or mesenchymal stem cells are described in Cellular Vesicles (2014) 3:23430. Detailed methods for harvesting extracellular vesicles or exosomes from cells are provided in the Examples. do.

[0081] The present invention provides methods for the immediate use of extracellular vesicles or exosomes, or for the storage and / or storage of exosomes in a cryogenic environment prior to use, for example. Alternatively, short-term and / or long-term storage of extracellular vesicles or exosomes in a cultured state Typically, proteinase inhibitors are used to prevent the formation of extracellular vesicles during long-term storage. It is included in the freezing medium because it ensures the integrity of exosomes. , which is undesirable since it is associated with a significant loss of extracellular vesicle or exosome activity. Rapid freezing at -80°C is more preferred as it preserves activity. See Kidney International (2006) 69, 1471-1476, which is incorporated herein by reference. The additives listed below are used to enhance the preservation of the biological activity of extracellular vesicles or exosomes. Such additives are similar to those used for cryopreservation of intact cells. Examples of suitable solvents include, but are not limited to, DMSO, glycerol, and polyethylene glycol. It can be seen.

[0082] F. Evaluating the Potency of Extracellular Vesicles or Exosomes The present invention provides a method for the treatment of hypoxia-induced PAH in a mouse model using extracellular vesicles or exosomes. To measure the impact of therapeutics and to identify robust populations of extracellular vesicles or exosomes In some embodiments, the present invention provides the use of right ventricular systolic pressure (RVSP) to measure extracellular A robust population of vesicles or exosomes was observed in PBS-bagged cells after 3 weeks of chronic hypoxia exposure. At least about 10%, 12.5%, 15%, and 17% 0.5%, 20%, 22.5%, 25%, 27.5%, or 30% chronic hypoxia for 3 weeks It is possible to lower the RVSP of mice subjected to state exposure.

[0083] In some embodiments, the delta RVSP potently binds extracellular vesicles or exosomes. As used herein, delta RVSPs are extracellular vesicles or exosomal proteins. The RVSP of hypoxic mice treated with rituximab was compared with that of normoxic mice. In some embodiments, the delta RVSP is defined as about 6, 5, 4, 3, or 2 m. Below mHg, the population of extracellular vesicles or exosomes is robust.

[0084] In some embodiments, the efficacy of a population of extracellular vesicles or exosomes is determined by the expression of the vesicles in smooth muscle cells ( SMC) lysate 2 They are characterized by their ability to increase consumption. In some embodiments, a robust population of extracellular vesicles or exosomes is observed after 24 hours of hypoxic conditions. At least about 10% compared to control SMC cell lysates exposed to the toxin and treated with PBS control , 15%, 20%, 25%, 30%, 35%, or 40% hypoxia exposure for 24 hours O2-treated SMC lysate 2 Consumption can be increased.

[0085] In some embodiments, the efficacy of a population of extracellular vesicles or exosomes is evaluated by their PK In some embodiments, the extracellular vesicles or exosomes are characterized by their activity. The potent population is at least about 0.15 nmol / min / ml, 0.16 nmol / min n / ml, 0.17nmol / min / ml, 0.18nmol / min / ml, 0.1 9nmol / min / ml, 0.20nmol / min / ml, 0.21nmol / mi n / ml, 0.22nmol / min / ml, 0.23nmol / min / ml, 0.2 4nmol / min / ml, 0.25nmol / min / ml, 0.3nmol / min / ml, or PK activity of 0.4 nmol / min / ml.

[0086] In some embodiments, the potency of a population of extracellular vesicles or exosomes is determined by their LD In some embodiments, the extracellular vesicles or exosomes are characterized by H activity. The efficacy of the population is to reduce LDH secreted by hypoxia-exposed SMCs by at least about 10%, They are characterized by their ability to reduce the

[0087] In some embodiments, the extracellular vesicles or exosomes of the present invention are selected from the group consisting of one of the following tables: Or isolate based on multiple criteria:

[0088] [Table 2]

[0089] In some embodiments, the isolated extracellular vesicles or exosomes are derived from whole cells of mesenchymal stromal cells. At least 10% and 20% higher than the average level of mir204 in extracellular vesicles or exosomes %, 30%, 50%, or greater than 100% of mir204.

[0090] In some embodiments, the isolated extracellular vesicles or exosomes are derived from whole cells of mesenchymal stromal cells. The average levels of CD105, GAPDH, DLST, and and / or ATP5A1 by at least 10%, 20%, 30%, 50%, or 100% % or more of CD105, GAPDH, DLST, and / or ATP5A1 .

[0091] In some embodiments, the isolated extracellular vesicles or exosomes are derived from whole cells of mesenchymal stromal cells. SORCS1, FHIT and / or ANKRD30 in extracellular vesicles or exosomes at least 10%, 20%, 30%, 50% or higher than the mean level of RNA expression in BL More than 100% of RNA expression of SORCS1, FHIT and / or ANKRD3 Includes 0BL.

[0092] In some embodiments, the isolated extracellular vesicles or exosomes contain low levels of MHCII contaminants. or little or no MHCII contaminants, e.g., mesenchymal stroma. Less than the average level of MHCII contaminants in all extracellular vesicles or exosomes of a cell 50%, 70%, 80%, 90%, 95%, 98%, or 99% less MHC Contains II contaminants.

[0093] In some embodiments, the isolated extracellular vesicles or exosomes contain low amounts of fibronectin. Inclusions or little or no fibronectin, e.g., mesenchymal Less than the average level of fibronectin in total extracellular vesicles or exosomes of stromal cells 50%, 70%, 80%, 90%, 95%, 98%, or 99% less fibrin Includes lonectin.

[0094] G. Treatment with Extracellular Vesicles or Exosomes Compositions useful in the methods of the present disclosure are particularly suitable for local injection, including catheter administration, systemic injection, topical injection, and / or intravenous administration. The present invention can be administered by oral injection, intravenous injection, intrauterine injection or parenteral administration. When administering the therapeutic compositions (e.g., pharmaceutical compositions) described herein, they are generally administered by injection. The pharmaceutical composition may be formulated into a unit dosage form, such as a solution, suspension, or emulsion.

[0095] The present invention relates to a method for treating cancer by administering extracellular vesicles or exosomes in a single dose, such as two, three, four, five or more doses. Single or repeated administration of extracellular vesicles or exosomes is contemplated, including administration via intravenous administration. In embodiments, the extracellular vesicles or exosomes can be administered continuously. or continuous administration may be over a period of several hours (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-10, 1-2, 1-3, 1-4 ... ~6, 1-12, 1-18, or 1-24 hours), or for several days (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, or 1-7 days), or for several weeks (e.g., 1-2 weeks) The administration may be continuous (for 1-3 weeks, 1-4 weeks, or 1-5 weeks). If the administration is repeated, the time between doses may be several hours (e.g., 4, 6, or 12 hours). ), a few days (e.g., 1, 2, 3, 4, 5, or 6 days), or a few weeks (e.g., For example, one week, two weeks, three weeks, or four weeks. The time between doses is the same. or they may be different. In one example, the symptoms of a disease may worsen. If symptoms persist, extracellular vesicles or exosomes can be administered more frequently and then After stabilization or reduction, extracellular vesicles or exosomes can be administered less frequently. do.

[0096] The present invention relates to the repeated administration of extracellular vesicles or exosomes in small doses and to the administration of cellular Single dose administration of extracellular vesicles or exosomes is also contemplated. Small dose forms include, but are not limited to, 1 kilogram. and the dosage form may range from 1 to 50 micrograms per kilogram, while multiple dosage forms may range from 1 to 50 micrograms per kilogram, but are not limited to this. The range may be from 51 to 1000 micrograms per gram. Depending on the elephant's health status and route of administration, low or high doses of extracellular vesicles or exosomal proteins may be administered. It will be understood that single or multiple administrations of the therapy are contemplated by the present invention.

[0097] Extracellular vesicles or exosomes are typically administered in combination with a pharma- ceutically acceptable carrier. , for use (e.g., administration) in a pharma- ceutically acceptable preparation (or pharma- ceutically acceptable composition). The phrase "pharmacologically acceptable" means a compound that is within the scope of sound medical judgment. has been used in humans and animals without excessive toxicity, irritation, allergic reactions, or other problems or complications. Suitable for use in contact with animal tissue and has a reasonable benefit / risk ratio As used herein, the term "pharmaceutical product" refers to a compound, substance, composition, and / or dosage form that is A "pharmaceutical acceptable carrier" refers to a pharmaceutically acceptable substance, composition or vehicle, e.g., It means a liquid or solid filler, diluent, excipient, or solvent, an encapsulating substance.

[0098] Such preparations typically contain pharma- ceutically acceptable concentrations of salts, buffers, preservatives, and compatible carriers. It may contain, and may optionally contain, other (i.e., secondary) therapeutic agents. A pharmaceutical acceptable carrier is a pharmaceutical agent that is involved in carrying or transporting a prophylactically or therapeutically active agent. a substance, composition or vehicle acceptable to the subject, such as a liquid or solid filler, diluent, excipient, Each carrier must be compatible with the other ingredients of the formulation. It must be "acceptable" in the sense that it is pharmacologic and not harmful to the subject. Some examples of substances that can act as carriers for the synthesis of glycerol include lactose, glucose and sucrose. sugars such as maltose, glycols such as propylene glycol, glycerin, sorbitol, mannose, Polyols such as ethyl acetate and polyethylene glycol, ethyl oleate and lauryl acetate esters such as ethyl acrylate, buffers such as magnesium hydroxide and aluminum hydroxide agents, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer There are buffer solutions and other non-toxic compatible substances utilized in pharmaceutical formulations.

[0099] The preparations of the present invention are administered in effective amounts. An effective amount is an amount of an agent that alone produces a desired result. Absolute amounts depend on the substance chosen for administration, whether the administration is a single or multiple dose. and individual patient characteristics, including age, physical condition, size, weight, and stage of disease. These factors are well known to those skilled in the art and depend on a variety of factors, including the parameters of and can be dealt with without going beyond routine experimentation.

[0100] The present invention also encompasses packaged and labeled pharmaceutical products. The container is a hermetically sealed glass vial, or plastic ampoule, or other container. The unit dosage form can be, for example, in a suitable container or vessel. The article or kit must be suitable for pulmonary delivery by aerosol. It is preferred that the composition further comprises instructions regarding how to use the composition, including how to administer the composition. Advise health care professionals, technicians, or subjects on appropriate prevention or treatment of the disease or disorder in question. In other words, the article of manufacture may further include informational material to assist in the administration of the actual dose, monitoring, and Dosage regimens, including but not limited to, procedures, and other monitoring information Includes instructions indicating or suggesting the following.

[0101] As with any pharmaceutical product, packaging materials and containers may affect the integrity of the product during storage and shipping. The kit contains MSC extracellular matrix suspended in a sterile aqueous suspension. It can contain vesicles or exosomes, which can be used directly or intravenously. It can be diluted with normal saline for intravenous injection or use in a nebulizer; For intratracheal administration, it may be diluted or combined with a surfactant. The kit may also contain a diluent solution or agent, such as saline or a detergent. EXAMPLES

[0102] The following examples provide a complete disclosure of how to make and use the methods and compositions described herein. These and other descriptions are meant to provide a person skilled in the art with a basic understanding of the present invention and are not meant to be limiting.

[0103] Example 1 - Isolation of exosome populations This example demonstrates the isolation of exosomes from cell culture medium.

[0104] Filtration: The conditioned medium obtained from mesenchymal stem cells (MSCs) was filtered through a 5 ml filter with a 0.2 um filter. Collected in a Sartorius-stedium Flexboy® bag of L The harvested conditioned medium was pumped through a filter line to remove any cells, Dead cells and cell debris were immediately removed. The conditioned medium consisted of 140 ml of Luer-Lo Use a syringe to refill the 25 mM HEPES and 10 mM EDTA buffer. did.

[0105] Tangential flow filtration: 5 L Flexboy® containing conditioned medium The bag was then connected to a Flexboy bag via a sample line that was connected to the top of the TFF vessel. , and connected to a tangential flow filtration (TFF) system. MWCO 0.1m 2 Sartori with Hydrosart® cassette US Sartocon Slice TFF was used. Underwater integrity testing was performed on each TFF run. The cassette was then flushed with 1 L of PBS. The medium samples were then gravity fed into the vessels. TFF was performed at 600 LMH. The 5 L volume of the initial medium was concentrated to 100 mL (50-fold concentration). The retentate was collected and diluted with 0. The filtrate was filtered using a 22um filter. The filtrate was divided into 10mL aliquot samples and The mixture was frozen at 37°C.

[0106] Fractionation: Samples were thawed at 37°C for approximately 10 min. All samples were placed in a 150 ml Corning bottle. The eluates were pooled together in a corning bottle. Sepharose CL-2B resin ( The XK50 / 100 column was packed using AKT A Aant150 (GE) was connected. The sample was introduced into the column via the sample line. After the entire sample was loaded onto the column, the elution step was started (flow rate: 4.6 ml / min). The column was eluted for 0.2 CV, and then the fractions were collected in a fraction collector. Collection of fractions was started at a rate of 1 min (4.6 ml per fraction). 0.6 CV was eluted. Fractions were collected until the exosomes were eluted between 0.3 and 0.4 CV. PBS was used throughout the study. Fractions were stored under a hood, capped, and at 4°C. .

[0107] Diafiltration: preferably after the TFF step and before the fractionation step, The sample is optionally subjected to a diafiltration step, similar to buffer exchange. After the desired concentration of exosomes is reached, the exosomes are pumped onto the TFF cassette filter. While continuing to move the tube, PBS buffer was added to the sample through the container to maintain the volume. The conditioned medium was replaced with PBS at 37 °C. Seven total volumes of PBS were added to ensure as complete an exchange as possible. Diafiltration was performed on the retentate. This step had no effect on the exosomes. It helps remove some of the impurities in the retentate without imparting too much total protein and phosphorus. The presence of lipid-bearing exosomes was confirmed by FLOT-1 Western blot.

[0108] Measurement of phospholipid concentration: Using phospholipid signaling for exosome detection. Briefly, after fractionation, 20 uL of each exosome preparation and 80 uL of reaction mixture (Si gma) in a clear-bottom 96-well plate (Corning, Corning, NY ) and incubated at room temperature for 30 minutes protected from light. ega microplate reader (BMG Labtech, Ortenberg, Germany) The fluorescence intensity was measured at 530 / 585 nm using a fluorochrome platelet filter. In this study, both A280 chromatogram and phospholipids were used to detect exosomes.

[0109] As shown in Figure 1C, phospholipid signaling is involved in the A280 There is good agreement with the chromatogram.

[0110] Example 2 - Treatment of Pulmonary Arterial Hypertension (PAH) in a Mouse Model Mice were subjected to 3 weeks of chronic hypoxia exposure (as indicated by an increase in right ventricular systolic pressure) P Exosome treatment consisted of a single tail vein injection prior to hypoxia exposure. Ta.

[0111] Example 3 - Identification of a potent exosome population To identify potent exosome populations, each exosome preparation was stained with PKM2 antibody (C Pyruvate kinase protein was assayed using the ELISA kit (Headquarters: Wells Signaling, Danvers, MA). Capillary electrophoresis immunoassays were performed according to the manufacturer's protocol. The samples were analyzed using a WES™ instrument (ProteinSimple, San Jose, CA) according to the call. Briefly, 4.2 uL of sample was added to the master fluorescence mixture (Pr The samples were then heated at 95°C for 5 min and then cooled to ice. Primary PKM2 antibody was diluted 1:1 in antibody diluent (ProteinSimple). A proprietary anti-rabbit secondary antibody (ProteinSimple) was used, diluted at 5%. The compound was synthesized by mixing 1:1 fluoride and Luminol-S (ProteinSimple). A chemiluminescent substrate was prepared. Sample, blocking reagent, primary antibody, secondary antibody, chemiluminescent substrate, and wash buffer were filled into designated wells in the provided microplate. The wells were spun at 1,000 g for 5 minutes to remove air bubbles. The cartridges were loaded into the WES instrument. After loading the plates, fully automated electrophoresis and immunoassays were performed. Protein detection was performed in a capillary system using the WES standard experimental setup. The proteins were separated. The data were analyzed using the built-in Compass software (ProteinSimple ) to obtain peak molecular weight signals and area under the curve values ​​per sample.

[0112] Pyruvate kinase activity: Pyruvate kinase converts one molecule of pyruvate to one molecule of ATP. catalyzes the transfer of phosphate from phosphoenolpyruvate (PEP) to ADP, resulting in Pyruvate kinase is an enzyme in glycolysis. PEP and ADP are catalyzed by PK to produce pyruvate and ATP. The pyruvate is oxidized by pyruvate oxidase, producing color (λ = 570 nm). The intensity of the color is proportional to the amount of pyruvic acid, so PK activity can be measured. In a kinetic assay, data analysis can be performed using the following equation: can: PK activity = (pyruvate x dilution factor) / (T2-T1) x well volume

[0113] In the above formula, T2-T1 is the time (in minutes) between time point 2 and time point 1. l) is calculated using a pyruvate standard curve (in this case pyruvate is the maximum (Calculate the final pyruvate concentration minus the initial pyruvate concentration at T1.) This number It is important that the activity measurements are within the linear range. Data sets can be analyzed at multiple time points. The best method to choose is to plot the curves. Select data points that are at least 2 minutes apart within the linear range. Each sample in the experiment is analyzed in the same way. In this experiment, T1 = 2 min, T2 = 4 min are selected. These two time points were chosen because they were well within the linear range.

[0114] Next, pyruvate kinase activity was measured for each exosome preparation treatment above the hypoxic control. The results were plotted against the in vivo RVSP fold change under each condition. It is possible to compare the fold improvement in RVSP by rhabdomyolysis and pyruvate kinase activity. See A. Pyruvate kinase activity was also plotted against delta RVSP. Delta RV SP is the hypoxic minus normoxic control treated with exosome conditions. Figure 2B Ref. Red dots represent potent exosome populations that induced significant improvement in RVSP. Blue dots show exosomes are not potent in treating hypoxia-induced PAH mice The pyruvate kinase activities of these most potent exosome populations were then boxed. The results are shown in a whisker plot. See FIG. 2C. The graph in (C) shows the most potent 13 shows the range of pyruvate kinase activity in various exosome preparations.

[0115] Example 4 - Proteomic and RNAseq analysis of a potent exosome population. For proteome analysis, exosome samples were transferred to Bioproximity (Chant The enriched exosomes were compared to the non-enriched exosome populations. Proteins whose expression levels were increased in the population are shown in FIG. 3(a).

[0116] Exosome samples were sent to SBI for RNAseq analysis. Genes with increased expression levels in the potent exosome population compared to the murine population are shown in Figure 4. As shown in.

[0117] Example 5 - Extracellular O 2 Measurement of consumption] abcam extracellular O 2 Use the consumption assay kit (ab197243) to measure normoxia State or 4% O 2 After 24 h of exposure to either hypoxia, PBS (control) or The oxygen consumption of exosome-treated smooth muscle cell (SMC) lysates was measured. As the digestion consumes oxygen via the electron transport chain, oxygen becomes depleted in the surrounding culture medium, and this This is seen as an increase in phosphorescence signal. Protect the microenvironment from the diffusion of O 2 Quenching of the probe The phosphorescence signal is measured as the area under the curve. The gradients were calculated in two ways as the gradient versus time (data analysis using the gradients was performed). Figure 5A-5B show that exosomes are induced by exposure to normoxia. Cells in MC 2 However, we demonstrate that it does not significantly change consumption. Xoxosome therapy reduces O2 production under hypoxic stress 2 This induces increased consumption of It shows an increase in a function.

[0118] Example 6 - Microarray analysis of SMCs exposed to acute hypoxia. Smooth muscle cells (SMCs) were treated with either PBS control or exosomes (EXSM). and normoxia or hypoxia (4% O 2 ) conditions for 24 hours. RNA from SMCs was isolated and analyzed using a global microarray platform. The results were sent to Qiagen for further investigation. Figures 6A-6C show the effect of acute hypoxia exposure on glucose uptake. We show that there is an increase in gene expression in metabolism. EXSM treatment increases (a) glycolysis, (b) (c) normalized this response in the TCA cycle and the electron transport chain. These data Exosomal pathways may be due to EXSM protein or gene incorporation into these pathways. Therapeutic strategies for the genetic upregulation of glucose oxidation genes during hypoxic stress This suggests that the need for

[0119] Example 7 - Metabolomic analysis of SMCs exposed to acute hypoxia Smooth muscle cells (SMCs) were treated with either PBS control or exosomes (EXSM). and normoxia or hypoxia (4% O 2 ) conditions for 24 hours. Cell lysates were pelleted and analyzed using Metabolon Immunosorbent Assay (MIL-MS). (North Carolina). As shown in Figure 7, the SMC lysate , and in glycolysis, TCA cycle, and energy metabolism pathways after acute hypoxia exposure. These results suggest that exosome therapy may be effective in reducing metabolic disease. (a) glycolysis and (b) flux through the TCA cycle were increased (due to reduced metabolic product build-up). These data show an increase in glucose oxidation. Acute hypoxia exposure reduces the levels of adenosine and nicotinamide adenine, the building blocks of ATP and NAD. We show that this resulted in the assembly of exosomes, possibly due to increased ATP production. Treatment has led to the use of adenosine and nicotinamide riboside (c). ATP production was measured in exposed viable SMCs (d), and EXSM-mediated increased ATP production confirmed.

[0120] Example 8 - Additional Methods Mouse model: C57BL / 6 mice were hypoxic at controlled oxygen levels of 10% oxygen for 3 weeks. The mice were placed in an oxygen tent to induce pulmonary hypertension. A single dose was injected into the tail vein 3 hours before exposure to the naïve state.

[0121] Isolation and analysis of exosomes: Serum-free conditioned medium was extracted from confluent MSC cultures over a 40-hour period. The conditioned medium was concentrated 50-fold using tangential flow filtration. was incubated with a fluorescent lipophilic dye, DiI, and then stained with Sepharose CL-2B Fractionation was performed using a resin-packed XK50 / 100 column (GE Heathcare). Exosome-containing fractions were identified by fluorescent detection of DiI and phospholipid quantification. RNA sequencing of selected fractions was performed using System Biosystems. Proteomics of selected fractions was performed by Biosciences (CA). The results were analyzed by Bioproximity using LC-MS / MS (Chanti Pyruvate kinase protein and enzyme activity were determined using Protein inSimple immunoassays and colorimetric kinetic assays (Abcam, ab8 3432).

[0122] In vitro model: Smooth muscle cells (SMCs) were cultured under normoxic or hypoxic conditions ( The mice were treated with PBS or exosomes for 24 hours in either 4% oxygen. for microarray analysis using the mina platform (Qiagen) or HD For metabolomics analysis using 4 platforms (Metabolon, RTP, NC) Experimental replicas were processed at 100°C. Oxygen consumption was measured using the Abcam Extracellular O2 Consumption Assay Kit ( Measurements were performed using a 100% chromatographic method (Abcam, ab197243).

[0123] Alveolar cells were inoculated for 24 h, transferred to 0.1% FBS medium, and incubated in a normoxic incubator. The cells were primed with the enriched exosome population for 3 hours in 0.1% CO2 and incubated in hyperoxic conditions. The plates were then cultured in a chamber for 48 hours (Figure 17).

[0124] SMC chronic hypoxia model: SMCs proliferate and do not undergo apoptosis under PAH and hypoxia This changes the patient's phenotype to a pulmonary edema, leading to enlargement of blood vessels and arteries in the lungs, causing high pressure and ultimately heart failure. It is known that SMC causes damage to the blood and negative symptoms in PAH. Normoxia, hypoxia (4% oxygen), and hypoxia (4% oxygen) + exosomes During the culture period, cells were treated with potent exosomes twice a week for two weeks. The generated SMCs were analyzed by microarray gene expression (IPA) and / or global meta-analysis. Analyzed by bolomics.

[0125] Example 9 - In vitro treatment with unexisomes In vitro experiments have demonstrated that unicellular endothelial cells have immunomodulatory capabilities. As shown in Figure 18, unixosome treatment significantly improved the oxidative stress response of cells exposed to hyperoxia. The increased immunomodulatory capacity of the cells was due to the decreased expression of IL-6 (hyperoxia was As shown in Figure 19, unixosome treatment increased the oxygen Increased immunoregulatory capacity in cells exposed to excessive stress due to decreased expression of TNFα (hyperoxia causes the release of TNFα).

[0126] The anti-apoptotic effect of unexisomes was also demonstrated by in vitro experiments. As shown in Figure 20, unexisome treatment increased cell numbers. Anti-apoptotic effect under hyperoxia conditions, as indicated by the corresponding increase in absorbance. As shown in FIG. 21, unixosome treatment reduced hyperoxia stress. reduced cytochrome C release from cells exposed to

[0127] Unexisomes can be used to promote pulmonary angiogenesis in BPD, as demonstrated in vivo This is further substantiated by in tro experiments. As shown in FIG. 22A, Treatment can restore tube formation during acute hyperoxia exposure.

[0128] Improving mitochondrial metabolism in BPD-associated PAH using unexisomes This has been further demonstrated by in vitro experiments. As shown, global metabolite analysis of intermediate metabolites in the pathway revealed that the unicellular endothelium is a chronic As shown in FIG. 25, unexcitatory hypoxia upregulated amino acid metabolism. The soma upregulated pyruvate and glutamate metabolism during chronic hypoxia.

[0129] As shown in FIG. 26, unixosomes upregulate the GLUD1 gene under chronic hypoxic conditions. As shown in Figure 27, unixosome expression was upregulated under chronic hypoxia. As shown in FIG. 28, unixosomes were down-regulated under chronic hypoxia. SIRT4 gene was down-regulated in the in vitro PAH model. The SIRT4 gene inhibits two metabolic enzymes, GLUD1 and PDH, in tumors. In an in vitro PAH model, it was downregulated by uniexosome treatment, whereas GL UD1 and PDH were upregulated by exosome treatment. SIRT4 was upregulated by exosome treatment. As shown in Figure 29, unixosomes are thought to be a target for hypoxia treatment. Restores TCA cycle function by upregulating genes downregulated in (6 of the 9 enzymes in the TCA cycle are down-regulated).

[0130] Example 10 - In vivo treatment with unexisomes Testing hyperoxia-induced BPD: C57BL / 6 mice from postnatal day (PN) 1 They were given 75% oxygen until the 7th day, and room air and normoxia from the 7th to the 14th day after birth. At PN4, a single dose of potent exosomes was injected into the superficial temporal vein. At PN7 and PN14, RNA and histological analyses were performed (Figure 38).

[0131] Testing for BPD-induced PAH: C57BL / 6 mice were treated with They were placed on 75% oxygen until postnatal day 7 and then on room air and normoxic levels from postnatal day 42. At PN4, a single dose of potent exosomes was injected into the superficial temporal vein. At PN14 and PN22, RNA, histological and cytometric analyses were performed. At PN42, histological and Blood count and complete blood count analysis were performed, as well as additional physiological measurements, pulmonary function tests, and RV pressure measurements. (Figure 38).

[0132] Combination therapy: C57BL / 6 mice were treated with 10% oxygen from day 1 to day 29, and The mice were then transferred to normal conditions from day 1 to day 56. On day 1, the mice were injected with semaxanib, and on day 2, the mice were injected with semaxanib. From the 9th to the 56th, sildenafil was administered twice daily and exosomes were administered once every 3 days. Mice were injected with RVSP and RVSP levels were measured (Figures 45A-B).

[0133] As shown in Figure 40, unexisome treatment rescued BPD-associated alveolar simplification. 40A shows that treatment with potent exosomes reduces hyperoxia compared to normoxia (NRMX). Figure 40B shows that the mean alveolar compaction was rescued by HYRX-mediated augmentation of alveolar compaction. Quantification of mean alveolar diameter, which represents a surrogate for interstitial diameter, is shown.

[0134] As shown in Figures 42A-C, unexisome treatment rescues chronic alveolar compaction. Figure 42A shows the results of the analysis of cells under normoxic and hypoxic conditions, as well as Wharton's jelly. Images of cells treated with BM-derived exosomes and BM-derived exosomes are shown in Figure 4. 2B: Exosomes rescued alveolar simplification in a BPD-associated PAH mouse model. Figure 42C shows collagen deposition in the septal area in a mouse model of BPD-associated PAH. As shown by the results of the study, exosomes reduced low-grade pulmonary fibrosis.

[0135] As shown in Figure 43A-D, unixosome therapy rescued pulmonary vascular remodeling in PAH patients. Figure 1 shows that the α-smooth muscle actin staining (A and B) and the PAH-related The PV loop is in the oxygen excess (HYRX) state. demonstrated a significant shift in lung function when compared to normoxic (NRMX) controls. Exosomes are a key component of this shift in lung function, as they are characteristic of lung disease such as pulmonary edema and air entrapment. Significant relief was demonstrated indicating improved function.

[0136] As shown in Figure 44A to Figure 44B, MSC exosomes inhibited hypoxia-induced PAH As shown in Figures 45A-B, exo- prevented PAH in a mouse model. Combination therapy of sildenafil and gliomasozome was shown to be effective in treating the Sugen / hypoxia-induced PAH mouse model. As shown in Figure 46, exosomes reversed the transport of PAHs in the spleen. Amino acid metabolism was upregulated in the gen / hypoxia model.

[0137] Example 11 - Characterization of unexisomes As shown in Figure 32, a strong exosome was identified using size exclusion chromatography. Isolation of the exosome subpopulation (COM2) revealed that it is possible to obtain exosomes of non-ideal size as well as proteins and non-proteins. Significantly reduced compared to ultracentrifugation or gradient separation, which also isolates potent microvesicular contaminants. As shown in Figure 33, the isolated potent exosomes were ultra-cleared and They have a more uniform size and clearer images compared to isolated cardiac samples.

[0138] As shown in Figure 34, the isolated potent exosomes were free of MHCII contaminants. In contrast, commercially available exosomes from ZenBio contain MHCII contaminants. .

[0139] As shown in Figures 35A to 35B, size exclusion chromatography was performed based on Ponceau staining. Potent exosomes isolated by fluorouraphy express fibronectin and other proteins. The commercially available ZenBio ultracentrifuged preparation is free of fibronectin contaminants. Contains staining substances.

[0140] As shown in Figure 36, RNAseq clustering of potent populations and microvesicle contaminants In the analysis, potent exosomes (COM2) were differentially clustered from microvesicular contaminants. , which are enriched for SORCS1, FHIT and ANKRD30BL. As shown in Fig. 1, the potent exosome (COM2) induces high levels of GAPDH expression. It has a lower CT value than COM1, which corresponds to

Claims

1. A method for treating pulmonary hypertension comprising administering to a subject in need thereof a pulmonary hypertension agent obtained from mesenchymal stromal cells. Administering isolated extracellular vesicles or exosomes, The expression of exosomes in total extracellular vesicles or exosomes obtained from the mesenchymal stromal cells (a) genes in the glycolytic pathway; (b) genes in the TCA cycle; and (c) one or more expression products selected from the group consisting of genes in an electron transport chain. The method comprises administering to a subject an amount of an extracellular vesicle or exosome having increased expression of the gene encoding the compound.

2. The extracellular vesicles or exosomes are whole extracellular vesicles or exosomes obtained from the mesenchymal stromal cells. have at least 20% higher expression levels compared to the average amount of the same expression product in exosomes. The method of claim 1 , comprising expression of the product.

3. (a) Genes in the glycolysis pathway are PK, AGI, ALDO, ALDOA, ENO3, and GPI. , HK2, HK3, PFK, PGM, TPI, GAPDH, ENO, and PGAM. (b) the genes in the TCA cycle are selected from the group consisting of MDH2, OGDH, PC, and PDH; A1, PDHB, SDHA, SDHC, and SUCLG2; c) The genes in the electron transport chain are ETFA, ATPase, NDUFC2, NDUFB1, and N DUFS5, NDUFA8, NDUFA9, NDUFS2, SDHA, SDHC, UQC 2. The method of claim 1, wherein the IL-1 IL-1 gene is selected from the group consisting of RH1, Cox6c1, and Cox10. method.

4. The method of claim 1 , wherein the gene is PK.

5. The method of claim 1 , wherein the gene is an ATPase.

6. The isolated extracellular vesicles or exosomes enhance glucose oxidation in lung tissue of the subject. The method of claim 1 , wherein the normalization is performed.

7. The isolated extracellular vesicles or exosomes have a concentration of at least 0.15 nmol / min / mL The method of claim 1 , wherein the PK activity is

8. The isolated extracellular vesicles or exosomes were exposed to chronic hypoxia for 3 weeks and then incubated with PBS. The mice exposed to chronic hypoxia for 3 weeks had at least 10% higher oxidative stress compared to control mice treated with 10% 2. The method of claim 1, wherein the method is capable of lowering right ventricular systolic pressure (RVSP) in a mouse.

9. The isolated extracellular vesicles or exosomes were exposed to hypoxia for 24 hours and then incubated with PBS for 24 hours. At least 20% compared to control SMC cell lysates treated with light for 24 hours under hypoxia O2 exposure in SMC cell lysates 2 The method according to claim 1, wherein the consumption can be increased. How to.

10. A method for treating a disease or condition associated with mitochondrial dysfunction, comprising administering to said subject a The present invention provides a method for administering isolated extracellular vesicles or exosomes obtained from mesenchymal stromal cells to a subject in need thereof. and wherein the isolated extracellular vesicles or exosomes are whole cells obtained from the mesenchymal stromal cells. (a) the average amount of expression product in the glycolytic pathway, compared to the average amount of expression product in extracellular vesicles or exosomes; (b) genes in the TCA cycle, and (c) genes in the electron transport chain. Extracellular vesicles or exosomes having increased expression of one or more expression products selected from the A method comprising:

11. (a) Genes in the glycolysis pathway are PK, AGI, ALDO, ALDOA, ENO3, and GPI. , HK2, HK3, PFK, PGM, TPI, GAPDH, ENO, and PGAM. (b) the genes in the TCA cycle are selected from the group consisting of MDH2, OGDH, PC, and PDH; A1, PDHB, SDHA, SDHC, and SUCLG2, (c) Genes in the electron transport chain are ETFA, ATPase, NDUFC2, and NDUFB1 , NDUFS5, NDUFA8, NDUFA9, NDUFS2, SDHA, SDHC, U 11. The method according to claim 10, wherein the antibody is selected from the group consisting of QCRH1, Cox6c1, and Cox10. The method described.

12. The method of claim 10, wherein the gene is PK.

13. The isolated extracellular vesicles or exosomes have a concentration of at least 0.15 nmol / min / mL The method of claim 13, having a PK activity of

14. The method of claim 10, wherein the gene is an ATPase.

15. The isolated extracellular vesicles or exosomes enhance glucose oxidation in lung tissue of the subject. The method of claim 10, wherein the normalization is performed.

16. The disease or condition associated with mitochondrial dysfunction is characterized by the incorporation of mitochondrial deficiency in the subject. The method of claim 10, which is associated with a reduction in glucose oxidation in doria.

17. The disease or condition associated with mitochondrial dysfunction is Friedreich's ataxia. , Leber's hereditary optic neuropathy, Kearns-Sayre syndrome, lactic acidosis and cerebrovascular disease Mitochondrial encephalomyopathy with pulmonary embolism-like manifestations, Leigh syndrome, obesity, atherosclerosis amyotrophic lateral sclerosis, Parkinson's disease, cancer, heart failure, myocardial infarction (MI), Alzheimer's disease, Immersion disease, Huntington's disease, schizophrenia, bipolar disorder, fragile X syndrome, and chronic fatigue syndrome 11. The method of claim 10, wherein the compound is selected from the group consisting of:

18. To isolate extracellular vesicles or exosomes that can treat or prevent pulmonary hypertension 16. A method for producing a medicament for use in a pharmaceutical composition comprising the steps of: a. A step of preparing a culture medium for mesenchymal stromal cells containing extracellular vesicles or exosomes. P, b. At least a portion of the extracellular vesicles or exosomes from other components of the culture medium. Separating the components; c. Separating extracellular vesicles or exosome populations from other extracellular vesicles or exosome populations isolating, the population being total extracellular vesicles or total extracellular vesicles obtained from the mesenchymal stromal cells (a) genes in the glycolytic pathway, (b) genes in the glycolytic pathway, compared to the average abundance of their expression products in exosomes. ) genes in the TCA cycle, and (c) genes in the electron transport chain. expression of one or more expression products is increased; The method includes:

19. 18. The method of claim 17, wherein the extracellular vesicle or exosome population is isolated by phospholipid detection. The method described above.

20. (a) Genes in the glycolysis pathway are PK, AGI, ALDO, ALDOA, ENO3, and GPI. , HK2, HK3, PFK, PGM, TPI, GAPDH, ENO, and PGAM. (b) the genes in the TCA cycle are selected from the group consisting of MDH2, OGDH, PC, and PDH; A1, PDHB, SDHA, SDHC, and SUCLG2, (c) Genes in the electron transport chain are ETFA, ATPase, NDUFC2, and NDUFB1 , NDUFS5, NDUFA8, NDUFA9, NDUFS2, SDHA, SDHC, U 19. The method according to claim 18, wherein the antibody is selected from the group consisting of QCRH1, Cox6c1, and Cox10. The method described.

21. 19. The method of claim 18, wherein the gene is PK.

22. The method of claim 18, wherein the gene is APTase.

23. To isolate extracellular vesicles or exosomes that can treat or prevent pulmonary hypertension 16. A method for producing a medicament for use in a pharmaceutical composition comprising the steps of: a. A step of preparing a culture medium for mesenchymal stromal cells containing extracellular vesicles or exosomes. P, b. At least a portion of the extracellular vesicles or exosomes from other components of the culture medium. Separating the components; c. Separating different populations of extracellular vesicles or exosomes based on molecular weight; d. Treating hypoxia-exposed mice with different populations of extracellular vesicles or exosomes Step e. Normoxia mice, hypoxia-exposed mice, and the extracellular vesicles or exosomal cells Measuring right ventricular systolic pressure (RVSP) in hypoxic mice treated with . , f. A process for identifying a strong population of extracellular vesicles or exosomes based on the RVSP. Top The method includes:

24. RVSP and hypoxic states in mice exposed to hypoxia treated with extracellular vesicles or exosomes If the RVSP ratio in the mice exposed to the agonist is 0.85 or less, the extracellular vesicles or exosomes The method of claim 23, wherein the population of is potent.

25. The delta RVSP is less than 5, and the delta RVSP is treated with extracellular vesicles or exosomes. RVSP of hypoxic mice minus RVSP of normoxic mice. The method of claim 23, wherein the population of extracellular vesicles or exosomes is enriched.

26. In step c, different populations of extracellular vesicles or exosomes are identified by phospholipid detection. The method of claim 23, wherein the separation is performed by

27. A strong population of the extracellular vesicles or exosomes was obtained from the mesenchymal stromal cells. (a) the average amount of expression product in the glycolytic pathway, compared to the average amount of expression product in extracellular vesicles or exosomes; (b) genes in the TCA cycle, and (c) genes in the electron transport chain.

24. The method of claim 23, wherein the expression of one or more expression products selected from .

28. (a) Genes in the glycolysis pathway are PK, AGI, ALDO, ALDOA, ENO3, and GPI. , HK2, HK3, PFK, PGM, TPI, GAPDH, ENO, and PGAM. (b) the genes in the TCA cycle are selected from the group consisting of MDH2, OGDH, PC, and PDH; A1, PDHB, SDHA, SDHC, and SUCLG2, (c) Genes in the electron transport chain are ETFA, ATPase, NDUFC2, and NDUFB1 , NDUFS5, NDUFA8, NDUFA9, NDUFS2, SDHA, SDHC, U 24. The method according to claim 23, wherein the antibody is selected from the group consisting of QCRH1, Cox6c1, and Cox10. The method described.

29. 24. The method of claim 23, wherein the gene is PK.

30. 24. The method of claim 23, wherein the gene is an ATPase.

31. Extracellular vesicles or exosomes that can treat or prevent bronchopulmonary dysplasia A method for isolating comprising the steps of: a. A step of preparing a culture medium for mesenchymal stromal cells containing extracellular vesicles or exosomes. P, b. At least a portion of the extracellular vesicles or exosomes from other components of the culture medium. Separating the components; c. Separating different populations of extracellular vesicles or exosomes based on molecular weight; d. Treating hypoxia-exposed mice with different populations of extracellular vesicles or exosomes Step e. Normoxia mice, hypoxia-exposed mice, and the extracellular vesicles or exosomal cells Measuring right ventricular systolic pressure (RVSP) in hypoxic mice treated with . , f. A process for identifying a strong population of extracellular vesicles or exosomes based on the RVSP. Top Methods including:

32. 23. The method of claim 22, wherein the separation in step b is by size exclusion chromatography. The method according to claim 31.

33. The isolated extracellular vesicles or exosomes obtained according to claim 23 or claim 31 are included. A composition comprising:

34. 3. The isolated extracellular vesicles or exosomes have an average diameter of about 100 nm.

4. The composition described in claim 3.

35. The isolated extracellular vesicles or exosomes express FLOT and / or ANXA2. The composition of claim 33.

36. The isolated extracellular vesicles or exosomes are whole extracellular vesicles of the mesenchymal stromal cells or The expression of mir204 was increased compared to the average amount of mir204 in exosomes. The composition of claim 33.

37. The isolated extracellular vesicles or exosomes are capable of detecting CD105, GAP CD105, GAPD, and / or DH, DLST, and / or ATP5A1 levels compared to the mean levels Secreted from MSCs containing increased expression of H, DLST, and / or ATP5A1 The composition of claim 33.

38. The isolated extracellular vesicles or exosomes are whole extracellular vesicles or exosomes of mesenchymal stromal cells. and the average amount of SORCS1, FHIT and / or ANKRD30BL in endothelial cells. Increased RNA expression of SORCS1, FHIT and / or ANKRD30BL compared to The composition of claim 33.

39. The isolated extracellular vesicles or exosomes are substantially free of MHCII contaminants. The composition of claim 33.

40. The isolated extracellular vesicles or exosomes are substantially free of fibronectin. Item 34. The composition according to item 33.

41. A method for treating or preventing bronchopulmonary dysplasia comprising administering to a subject in need thereof a Administering the isolated extracellular vesicle or exosome according to any one of claims 31 to 40. The method includes:

42. The isolated extracellular vesicles or exosomes increase the immunomodulatory capacity of the subject.

42. The method according to claim 41.

43. The isolated extracellular vesicles or exosomes are administered to the subject to administer IL-6 and / or T 43. The method of claim 42, wherein the expression of NFα is reduced.

44. 41. The method of claim 41, wherein the isolated extracellular vesicles or exosomes promote angiogenesis in the subject. The method described above.

45. The isolated extracellular vesicles or exosomes are used to treat hyperoxia-induced apoptosis in the subject.

45. The method of claim 44, wherein the method reduces

46. The isolated extracellular vesicles or exosomes reduce cytochrome C levels in the subject. The method of claim 44,

47. The isolated extracellular vesicles or exosomes increase mitochondrial metabolism in the subject.

42. The method of claim 41 .

48. The isolated extracellular vesicles or exosomes restore tubulogenesis in the subject.

42. The method according to claim 41.

49. The isolated extracellular vesicles or exosomes are administered to the subject.

42. The method of claim 41, wherein PDH gene expression is upregulated.

50. The isolated extracellular vesicles or exosomes down-regulate PDK4 gene expression in the subject.

42. The method of claim 41 , wherein the

51. The isolated extracellular vesicles or exosomes reduce SIRT4 gene expression in the subject. The method of claim 41 , further comprising controlling the direction of the injection.

52. 41. The method of claim 1, further comprising administering sildenafil to the subject.

52. A method according to claim 51.

Citation Information

Patent Citations

  • Method for detecting therapeutic exosomes

    JP2014507140A

  • Methods and compositions related to mesenchymal stem cell exosomes

    JP2014507482A

  • Pulmonary hypertension therapeutic agent and screening method for the same

    JP2016056115A

  • Spray dry formulations

    WO2015054574A1

  • Exosome recovery methods with low molecular weight organic zwitterions

    WO2015060784A1